Clinical Trial Update: First in Human Pilot Study to Assess the Safety and Efficacy of Dendritic Cells Loaded With Frameshift Derived Neopeptides for the Prevention of Cancer in of Lynch Syndrome Carriers [Phase 1]

View source ↗

Summary

A first-in-human Phase 1 trial evaluating a dendritic cell vaccine loaded with frameshift-derived neopeptides to prevent cancer in Lynch syndrome carriers is cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Lynch Syndrome

Drugs mentioned

• Dendritic cell vaccine loaded with frameshift-derived neopeptides

Snippet

Sponsor: Fundacion Clinic per a la Recerca Biomédica | Conditions: Lynch Syndrome | Phase 1 | Status: RECRUITING